Company Overview and News
INFRACORP Development, Inc. is currently looking for an operations and maintenance (O&M) partner for its P3.5-billion Skytrain project, saying it is speaking with several firms from Austria, France, Japan and China.
ALGGY ALGGF AYAAY AGI ALI AYAAF
Megaworld Corp. is scaling up its residential project launches to P80 billion this year, banking on the continued strong demand for properties from both local and foreign buyers.
ALGGY GERI ALGGF AGI
GLOBAL-ESTATE Resorts, Inc. (GERI) is aiming to generate P8 billion in sales from its fifth residential condominium in Ortigas Center, banking on its proximity to educational institutions and key business districts.
ALGGY GERI ATB ALGGF AGI
THE infrastructure arm of tycoon Andrew L. Tan’s Alliance Global Group, Inc. (AGI) bagged the original proponent status (OPS) for its proposed P3-billion monorail project connecting Fort Bonifacio to the Guadalupe station of the Metro Rail Transit (MRT) Line 3.
FILIY JGSMY ALGGY RWM JGS MPI MPCFF MPCIY ALGGF FDC AGI JGSHF
The infrastructure arm of tycoon Andrew L. Tan’s Alliance Global Group, Inc. (AGI) bagged the original proponent status (OPS) for its proposed P3-billion monorail project connecting Fort Bonifacio to the Guadalupe station of the Metro Rail Transit (MRT) Line 3.
ALGGY ALGGF AGI
The group of tycoon Andrew Tan has bagged the original proponent status for the unsolicited proposal to build a P3-billion two-kilometer “Skytrain” monorail that will link Fort Bonifacio and MRT Guadalupe Makati.
ALGGY ALGGF AGI
THE Department of Transportation (DoTr) may grant within the next two weeks the original proponent status (OPS) to the consortium seeking to rehabilitate the Ninoy Aquino International Airport (NAIA).
JGSMY JGS MPCIY PXMFF GMQRY GMRINFRA 532754 FILIY PX ALGGY MWP MPI MPCFF ALGGF FDC AGI MWIDE PXMFY JGSHF
The four-hour train ride from King’s Cross in London began with an idyllic, rather flat countryside. Beyond the River Tweed, the terrain slowly transformed into a vast, rocky coastline, with the train weaving through roofed hamlets, rolling greens and acres of unblemished Scottish countryside.
ALGGY ALGGF AGI
THE CONSORTIUM formed by some of the country’s conglomerates has submitted a revised proposal to rehabilitate the Ninoy Aquino International Airport (NAIA), cutting the project duration from 35 years to 15 years.
JGSMY JGS MPCIY GMQRY GMRINFRA 532754 FILIY ALGGY MWP MPI MPCFF ALGGF FDC AGI MWIDE JGSHF
CONGLOMERATES are expected to register better financial results this year, as the country’s top firms proceed with expansion programs amid a new tax regime and challenges in their respective businesses.
JGSMY GTCAP GTCXY SVTMF SMCP1 JGS SM AEV SMGBF SMIVY SMC ALGGY MPCFF PHSXY PSE AGI JGSHF DMC PSKXF MPCIY LPZ DMCIF SMGBY DMCP SMC2B SMC2A SMC2D SMC2C ABTZY MPI SMC2F SMC2E ALGGF DMCHY LTG
Tycoon Andrew Tan-led conglomerate Alliance Global Group Inc. (AGI) posted P3.5 billion in first quarter net profit attributable to equity holders of parent firm, down by 2 percent year-on-year, on slower earnings from integrated gaming operations alongside higher interest charges and foreign exchange losses.
PSKXF ALGGY ALGGF PHSXY PSE AGI
A FUTURE government will end up making the decision to designate a main international gateway airport for Metro Manila, the National Economic and Development Authority (NEDA) said, due to the long timelines for the airports under development around the nation’s capital.
JGSMY SMCP1 JGS MPCIY SMGBY SMGBF FILIY SMC2B SMC2A SMC SMC2D ALGGY SMC2C MWP MPI MPCFF SMC2F SMC2E ALGGF FDC AGI MWIDE JGSHF
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET